Biontech to present progress across diversified oncology pipeline at the 2025 asco annual meeting

Mainz, germany, may 27, 2025 -- biontech se (nasdaq: bntx, “biontech” or “the company”) will present clinical trial data from select pipeline candidates across the company's diversified oncology portfolio at the american society of clinical oncology (“asco”) annual meeting, to be held in chicago, il, from may 30 to june 3, 2025. the data highlight continued progress of the company's clinical programs consisting of complementary therapeutic modalities, including mrna cancer immunotherapies, next-generation immunomodulators, and targeted therapies, including antibody-drug conjugates (“adcs”).
BNTX Ratings Summary
BNTX Quant Ranking